Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands

US7691856B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• PHARMACOPEIA, LLC · US

Inventors

• Arthur G. Taveras · Rockaway, US
• Jianhua Chao · Pompton Lakes, US
• Purakkattle Biju · Piscataway, US
• Younong Yu · East Brunswick Township, US
• Cynthia Aki · Livingston, US
• J. Merritt · Ewing, US
• Ge Li · Shanghai, CN
• John J. Baldwin · Gwynedd Valley, US
• Gaifa Lai · Edison, US
• Minglang Wu · Monmouth Junction, US
• Evan Hecker · Arlington, US

Key dates

• Filing date: Jan 9, 2007
• Grant date: Apr 6, 2010
• Expiry date: Apr 11, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are novel compounds of the formula:and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.